Indian MedTech Company Makes a Global Mark at PCR London Valves 2025
Nov 25, 2025
Vapi (Maharashtra) [India], November 25: Underscoring India's rising influence in global cardiovascular innovation, Meril Life Sciences presented the one-year outcomes from the pivotal LANDMARK Randomized Controlled Trial (RCT) during the Late-Breaking Trial sessions at PCR London Valves 2025, one of the world's most respected structural heart conferences. This milestone marks a significant moment for Indian MedTech, as the indigenous, balloon-expandable Myval THV series is directly compared with leading international transcatheter valve platforms from Edwards Lifesciences and Medtronic. As the first-ever multicenter RCT to evaluate an Indian-developed THV against these established global systems, the LANDMARK trial highlights the growing confidence, capability, and clinical credibility of India's cardiac device ecosystem on a global stage.
